E2 ModeratePreliminaryPEM not requiredRegistry-ResourcePeer-reviewedMachine draft
Standard · 3 min
Exploring the concept of vigor and dys-vigor in men of 50-65 years: effects of Robuvit®.
Ledda, Andrea, Hosoi, Morio, Cesarone, Maria R et al. · Panminerva medica · 2020 · DOI
Quick Summary
This small study tested whether a supplement called Robuvit® (made from oak wood extract) could help middle-aged men feel more energetic and less tired. Forty men aged 50-65 who felt exhausted took either standard lifestyle advice alone or the same advice plus the supplement for 4 weeks. Both groups improved, but the men taking Robuvit® reported significantly better energy levels and had lower markers of cellular stress in their blood.
Why It Matters
Although this study is small and preliminary, the authors cite prior evidence that Robuvit® may help chronic fatigue syndrome, suggesting biological plausibility for investigating antioxidant interventions in ME/CFS populations. The focus on oxidative stress as a measurable mechanism resonates with emerging mechanistic theories in ME/CFS research, making this a potential signal worthy of more rigorous investigation.
Observed Findings
Men receiving Robuvit® supplementation showed significantly higher vigor scores across all measured items compared to standard management alone after 4 weeks (P<0.05).
Plasma free radical levels (Carr Units) decreased significantly more in the Robuvit® group than the standard management group (P<0.05).
Both groups improved from baseline with standard management (diet, exercise, routine), indicating a general benefit of lifestyle intervention.
No adverse events or dropouts were reported in either group over the 4-week period.
All 40 enrolled subjects completed the study with reported good tolerability of the supplement.
Inferred Conclusions
Robuvit® supplementation enhances improvements in vigor beyond standard lifestyle management in middle-aged men with low vigor and elevated oxidative stress.
The antioxidant properties of Robuvit® may partially explain its effects on vigor, as measured by reduced plasma free radicals.
Vigor is a measurable and quantifiable construct that can be assessed in clinical studies and may be amenable to intervention.
Remaining Questions
Does Robuvit® produce similar effects in people with diagnosed ME/CFS, or only in age-related vigor loss without underlying organic disease?
What This Study Does Not Prove
This study does not prove Robuvit® is effective for ME/CFS patients; the sample consisted of healthy middle-aged men with age-related vigor loss, not individuals with ME/CFS. The lack of a placebo control and small unblinded design cannot exclude placebo effect or bias. The 4-week timeframe is too brief to assess long-term safety or durability of benefit.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionNo ControlsSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →